Pipeline

Pipeline

Overview

The Kyn Therapeutics pipeline addresses distinct immuno-metabolic targets. Each of these programs targets key metabolites in highly characterized pathways that drive immunosuppression in numerous cancer types.

Pipeline

The EP4 antagonist ARY-007 is held by Arrys Therapeutics, an affiliate of Kyn Therapeutics, and its development has been exclusively subcontracted to Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
1030 Massachusetts Avenue
Suite 400
Cambridge, MA 02138

Call us

1-857-273-8343

Email us

info@kyntherapeutics.com

Friend us

LinkedIn